id2725.html
In consultation: Guidance and quality standards
Sun, 09 Feb 2025 03:06:00 GMT
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725] Draft guidance Technology appraisal guidance 25 February 2025 Tarlatamab for previously treated ...